GlassScriptPhysician profile
Jonathan Charles Catrona
NPI 1568972859
$3,585.04
in general payments reported to CMS, 2019-2025
22 companies · $43.47 in 2025
The $43.47 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,052 · 2022: $243 · 2023: $290 · 2024: $956 · 2025: $43.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $788 · Food and Beverage: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $787.50 |
| Food and Beverage | $502.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $1,500.00 | 2021 | |
| Pharmaessentia USA Corporation | $787.50 | 2024 | Besremi |
| Novartis Pharmaceuticals Corporation | $481.08 | 2021-2025 | |
| Janssen Biotech, INC. | $151.93 | 2021-2023 | Imbruvica, Darzalex |
| Astrazeneca Pharmaceuticals LP | $99.95 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $84.44 | 2021-2022 | |
| Dova Pharmaceuticals | $65.31 | 2021 | |
| Cti Biopharma Corp. | $62.61 | 2023 | Vonjo |
| Celgene Corporation | $59.56 | 2023 | Pomalyst, Reblozyl |
| Genzyme Corporation | $58.69 | 2023 | |
| Abbvie INC. | $28.33 | 2025 | |
| Taiho Oncology, INC. | $27.50 | 2021 | |
| Pharmacosmos Therapeutics INC. | $22.59 | 2022 | |
| Mylan Institutional INC. | $22.08 | 2021 | |
| Global Blood Therapeutics, INC. | $19.44 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $18.28 | 2021 | |
| Seagen INC. | $17.69 | 2021 | |
| Astellas Pharma US INC | $17.24 | 2023 | Padcev |
| Incyte Corporation | $17.22 | 2021 | |
| Puma Biotechnology, INC. | $15.85 | 2021 | |
| Lilly USA, LLC | $15.73 | 2021 | |
| Eisai INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Catrona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.